Background: There is growing recognition and understanding of the entities that cause
interstitial lung disease (ILD) in infants. These entities are distinct from those that cause ILD …

In acquired pulmonary alveolar proteinosis, lipids and proteins accumulate within the alveoli
because alveolar macrophages cannot catabolize surfactants. Surprisingly, alveolar …

Pulmonary alveolar proteinosis is a rare clinical syndrome that was first described in 1958.
Subsequently, over 240 case reports and small series have described at least 410 cases in …

Pulmonary surfactant is a complex and highly surface active material composed of lipids and
proteins which is found in the fluid lining the alveolar surface of the lungs. Surfactant …

The alveolar region of the lung creates an extensive epithelial surface that mediates the
transfer of oxygen and carbon dioxide required for respiration after birth. Maintenance of …

Pulmonary alveolar proteinosis (PAP) is a rare pulmonary disease characterised by alveolar
accumulation of surfactant. It may result from mutations in surfactant proteins or granulocyte …

Pulmonary surfactants consist of phospholipids and the hydrophobic proteins surfactant
protein B and surfactant protein C. These surfactants keep the alveoli in the lung open to the …

The invention relates to a polyribonucleotide with a sequence that codes a protein or protein
fragment, wherein the polyri bonucleotide comprises a combination of unmodified and …

Pulmonary alveolar proteinosis (PAP) is a syndrome characterized by the accumulation of
alveolar surfactant and dysfunction of alveolar macrophages. PAP results in progressive …

Integrating basic and clinical research on the biophysical and physiological functions of
pulmonary surfactants, this practical reference presents thorough, cutting-edge coverage on …